Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

1998 ◽  
Vol 13 (4) ◽  
pp. 163-166 ◽  
Author(s):  
Daniel J. Wallace ◽  
Dennis Goldfinger ◽  
Samuel H. Pepkowitz ◽  
Marshal Fichman ◽  
Allan L. Metzger ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Lupus Nephritis ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Proliferative Lupus Nephritis ◽  
Pulse Synchronization

scholarly journals Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

2006 ◽  
Vol 70 (4) ◽  
pp. 732-742 ◽  
Author(s):  
C. Grootscholten ◽  
◽  
G. Ligtenberg ◽  
E.C. Hagen ◽  
A.W.L. van den Wall Bake ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Lupus Nephritis ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Proliferative Lupus Nephritis

scholarly journals Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: A randomized controlled trial

2019 ◽  
Vol 29 (5) ◽  
pp. 373
Author(s):  
KrishanLal Gupta ◽  
Joyita Bharati ◽  
Manish Rathi ◽  
Raja Ramachandran ◽  
Aman Sharma ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Lupus Nephritis ◽  
Induction Therapy ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Proliferative Lupus Nephritis

scholarly journals Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

2020 ◽  
Vol 383 (12) ◽  
pp. 1117-1128 ◽  
Author(s):  
Richard Furie ◽  
Brad H. Rovin ◽  
Frédéric Houssiau ◽  
Ana Malvar ◽  
Y.K. Onno Teng ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Lupus Nephritis ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review

2020 ◽  
Vol 20 (02) ◽  
pp. 47-55
Author(s):  
Natalia Chu Oi Ciang ◽  
Chi Chiu Mok
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Randomized Controlled Trial ◽  
Lupus Nephritis ◽  
Literature Review ◽  
Lupus Erythematosus ◽  
Low Dose ◽  
Controlled Trial ◽  
Systemic Lupus ◽  
Randomized Controlled ◽  
Multicenter Rct

Although glucocorticoids (GCs) are the cornerstone for the treatment for systemic lupus erythematosus (SLE), they are associated with a number of adverse effects. Recently, an open randomized controlled trial (RCT) conducted in France showed that flares of SLE in 12 months were significantly more common with GCs withdrawal than continuation in stable patients. However, the study did not separately report results on subsets of SLE patients with organ threatening disease such as lupus nephritis (LN). We hereby present a literature review on GCs withdrawal in SLE and propose a protocol for a multicenter RCT in Hong Kong to evaluate the feasibility of withdrawal of low-dose GCs in stable LN patients who are in clinical remission.

Sign in / Sign up

Export Citation Format

Share Document